Printed from Voxsanity (voxsanity.com.au) — NCT07343479 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 2 Lung Cancer Trial, Not Yet Recruiting
NCT07343479
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged 18 to 75 years old at the time of signing the consent form, of any gender.
- People whose lung cancer has been confirmed by laboratory testing of tissue or cell samples to be a non-squamous type of non-small cell lung cancer (NSCLC) that has spread to other parts of the body (Stage IV).
- People whose cancer has a confirmed specific gene change (EGFR mutation) — either a deletion in a region called exon 19, or a specific point change in exon 21 called L858R.
- People who have previously been treated with a type of targeted therapy called an EGFR-TKI for advanced or metastatic disease, and whose scans have shown the cancer has continued to grow or spread during that treatment.
- People who have brain metastases (cancer that has spread to the brain) — whether newly found or previously known — confirmed by a contrast-enhanced MRI scan of the brain.
- People with a general health and activity level rated as 0 or 1 on a standard medical scale called the ECOG scale (meaning fully active or able to carry out light activity).
- People with a life expectancy of at least 12 weeks.
- People whose liver, kidneys, blood cells, and other organs are functioning at an adequate level.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose cancer testing shows it contains small cell lung cancer, neuroendocrine carcinoma, carcinosarcoma, or squamous cell carcinoma components.
- People who have cancer that has spread to the membranes lining the brain and spinal cord (called leptomeningeal metastases).
- People who have had another type of cancer in the 3 years before starting the trial, except for certain cancers treated locally that are considered cured, such as some skin cancers or early-stage cervical cancer (confirm with trial site).
- People who have serious uncontrolled heart or blood vessel conditions, including severe heart failure, unstable chest pain (angina), a recent heart attack, uncontrolled irregular heartbeat, a specific abnormality on a heart tracing (QTcF interval over 470 ms), or other significant heart or stroke-related conditions within the 6 months before starting the trial.
- People who have uncontrolled serious conditions affecting the whole body, as assessed by the trial doctors.
- People with serious lung problems caused by other existing lung conditions, including a blood clot in the lungs within the past 3 months, severe asthma, severe chronic obstructive pulmonary disease (COPD), restrictive lung disease, fluid around the lungs, certain autoimmune or inflammatory diseases that can affect the lungs (such as rheumatoid arthritis or sarcoidosis), or people who have had a surgical removal of an entire lung.
- People with active ongoing bowel conditions such as inflammatory bowel disease, a blocked bowel, severe ulcers, a hole in the bowel, an abscess in the abdomen, or active severe bleeding in the digestive system.
- People who have previously had non-infectious lung inflammation (pneumonitis) or scarring of the lung tissue (interstitial lung disease) that needed steroid treatment, or who currently have these conditions.
- People with an active infection that requires treatment with medicines given throughout the body (such as intravenous or oral antibiotics or antiviral medicines).
- People with active hepatitis B or hepatitis C infection, confirmed by specific blood tests showing the virus is active above defined levels (confirm with trial site for exact thresholds).
- People who test positive for HIV, have a history of AIDS, or have a known active syphilis infection.
- People who have previously received a transplant of tissue or a solid organ from another person.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Contact this trial
Principal Investigator: Yun Fan, Doctor, Zhejiang Cancer Hospital
Phone: +8657188122092
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Zhejiang Cancer Hospital
Registry
ClinicalTrials.gov
Start date
1 May 2026
Est. completion
20 June 2027
Where this trial is recruiting
🇨🇳 China
Primary endpoints
6-month PFS rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.